83 related articles for article (PubMed ID: 33321427)
1. BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer.
Fan F; Zhou M; Ye X; Mo Z; Ma Y; Luo L; Liang X; Liu H; Weng Y; Lin M; Liu X; Cai X; Qian C
Transl Oncol; 2021 Feb; 14(2):100961. PubMed ID: 33321427
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
Cha MY; Lee KO; Kim M; Song JY; Lee KH; Park J; Chae YJ; Kim YH; Suh KH; Lee GS; Park SB; Kim MS
Int J Cancer; 2012 May; 130(10):2445-54. PubMed ID: 21732342
[TBL] [Abstract][Full Text] [Related]
3. Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors.
Wurz RP; Pettus LH; Ashton K; Brown J; Chen JJ; Herberich B; Hong FT; Hu-Harrington E; Nguyen T; St Jean DJ; Tadesse S; Bauer D; Kubryk M; Zhan J; Cooke K; Mitchell P; Andrews KL; Hsieh F; Hickman D; Kalyanaraman N; Wu T; Reid DL; Lobenhofer EK; Andrews DA; Everds N; Guzman R; Parsons AT; Hedley SJ; Tedrow J; Thiel OR; Potter M; Radinsky R; Beltran PJ; Tasker AS
ACS Med Chem Lett; 2015 Sep; 6(9):987-92. PubMed ID: 26396685
[TBL] [Abstract][Full Text] [Related]
4. YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFR
Zhang Z; Zou J; Yu L; Luo J; Li Y; Tu Z; Ren X; Wei H; Song L; Lu X; Ding K
Cancer Med; 2018 Apr; 7(4):1430-1439. PubMed ID: 29532998
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer.
Kim DH; Choi YJ; Kim SY; Lee JE; Sung KJ; Sung YH; Kim WS; Kim SE; Ryu HC; Kim JS; Guangying L; Choi CM; Rho JK; Lee JC
Target Oncol; 2018 Jun; 13(3):389-398. PubMed ID: 29754184
[TBL] [Abstract][Full Text] [Related]
6. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
Furugaki K; Fukumura J; Iwai T; Yorozu K; Kurasawa M; Yanagisawa M; Moriya Y; Yamamoto K; Suda K; Mizuuchi H; Mitsudomi T; Harada N
Int J Cancer; 2016 Feb; 138(4):1024-32. PubMed ID: 26370161
[TBL] [Abstract][Full Text] [Related]
7. Novel Selective and Potent EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer.
Li Y; Song Z; Jin Y; Tang Z; Kang J; Ma X
Molecules; 2016 Nov; 21(11):. PubMed ID: 27827863
[TBL] [Abstract][Full Text] [Related]
8. A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.
Jiang T; Su C; Ren S; Cappuzzo F; Rocco G; Palmer JD; van Zandwijk N; Blackhall F; Le X; Pennell NA; Zhou C;
J Thorac Dis; 2018 Jul; 10(7):3909-3921. PubMed ID: 30174832
[TBL] [Abstract][Full Text] [Related]
9. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
10. Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode.
Hu C; Wang A; Wu H; Qi Z; Li X; Yan XE; Chen C; Yu K; Zou F; Wang W; Wang W; Wu J; Liu J; Wang B; Wang L; Ren T; Zhang S; Yun CH; Liu J; Liu Q
Oncotarget; 2017 Mar; 8(11):18359-18372. PubMed ID: 28407693
[TBL] [Abstract][Full Text] [Related]
11. SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo.
Pan Y; Xu Y; Feng S; Luo S; Zheng R; Yang J; Wang L; Zhong L; Yang HY; Wang BL; Yu Y; Liu J; Cao Z; Wang X; Ji P; Wang Z; Chen X; Zhang S; Wei YQ; Yang SY
Mol Cancer Ther; 2012 Apr; 11(4):952-62. PubMed ID: 22319204
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing.
Tjin Tham Sjin R; Lee K; Walter AO; Dubrovskiy A; Sheets M; Martin TS; Labenski MT; Zhu Z; Tester R; Karp R; Medikonda A; Chaturvedi P; Ren Y; Haringsma H; Etter J; Raponi M; Simmons AD; Harding TC; Niu D; Nacht M; Westlin WF; Petter RC; Allen A; Singh J
Mol Cancer Ther; 2014 Jun; 13(6):1468-79. PubMed ID: 24723450
[TBL] [Abstract][Full Text] [Related]
13. T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non-Small Cell Lung Cancer.
Watanabe S; Yoshida T; Kawakami H; Takegawa N; Tanizaki J; Hayashi H; Takeda M; Yonesaka K; Tsurutani J; Nakagawa K
Mol Cancer Ther; 2017 Nov; 16(11):2563-2571. PubMed ID: 28839001
[TBL] [Abstract][Full Text] [Related]
14. A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice.
Slobbe P; Windhorst AD; Stigter-van Walsum M; Smit EF; Niessen HG; Solca F; Stehle G; van Dongen GA; Poot AJ
EJNMMI Res; 2015; 5():14. PubMed ID: 25853020
[TBL] [Abstract][Full Text] [Related]
15. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
16. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
[TBL] [Abstract][Full Text] [Related]
17. Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
Biochem Biophys Res Commun; 2013 Feb; 431(3):623-9. PubMed ID: 23266614
[TBL] [Abstract][Full Text] [Related]
18. Dual PI3K/HDAC Inhibitor BEBT-908 Exhibits Potent Efficacy as Monotherapy for Primary Central Nervous System Lymphoma.
Wang N; Mo Z; Pan L; Zhou M; Ye X; Liu X; Cai X; Qian C; Chen F; Xiong Y; Fan F; Li W
Target Oncol; 2023 Nov; 18(6):941-952. PubMed ID: 37855991
[TBL] [Abstract][Full Text] [Related]
19. AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations.
Zhao R; Zhou S; Xia B; Zhang CY; Hai P; Zhe H; Wang YY
BMC Cancer; 2016 Jul; 16():491. PubMed ID: 27431492
[TBL] [Abstract][Full Text] [Related]
20. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.
Freeman DJ; Bush T; Ogbagabriel S; Belmontes B; Juan T; Plewa C; Van G; Johnson C; Radinsky R
Mol Cancer Ther; 2009 Jun; 8(6):1536-46. PubMed ID: 19509246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
